AnaptysBio’s (ANAB) Outperform Rating Reiterated at Leerink Partnrs

Leerink Partnrs reissued their outperform rating on shares of AnaptysBio (NASDAQ:ANAB) in a research note issued to investors on Tuesday morning, Zacks.com reports. Leerink Partnrs also issued estimates for AnaptysBio’s Q1 2024 earnings at ($1.41) EPS, Q2 2024 earnings at ($1.44) EPS, Q3 2024 earnings at ($1.45) EPS, Q4 2024 earnings at ($1.42) EPS, FY2024 earnings at ($5.71) EPS, Q1 2025 earnings at ($1.91) EPS, Q2 2025 earnings at ($1.86) EPS, Q3 2025 earnings at ($1.85) EPS, Q4 2025 earnings at ($1.14) EPS, FY2025 earnings at ($6.37) EPS, FY2026 earnings at ($4.82) EPS, FY2027 earnings at ($3.95) EPS and FY2028 earnings at ($3.39) EPS.

Other research analysts also recently issued reports about the company. SVB Leerink initiated coverage on AnaptysBio in a research note on Tuesday. They issued an outperform rating and a $47.00 price target for the company. JPMorgan Chase & Co. reduced their target price on AnaptysBio from $30.00 to $28.00 and set a neutral rating for the company in a research note on Monday, April 1st. Piper Sandler started coverage on AnaptysBio in a research note on Friday, February 16th. They set an overweight rating and a $80.00 target price for the company. Stifel Nicolaus started coverage on AnaptysBio in a report on Wednesday, February 21st. They set a buy rating and a $50.00 price target for the company. Finally, Wedbush raised AnaptysBio from a neutral rating to an outperform rating and lifted their price target for the stock from $20.00 to $34.00 in a report on Tuesday, March 12th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, AnaptysBio presently has an average rating of Moderate Buy and an average price target of $46.22.

AnaptysBio Price Performance

NASDAQ ANAB opened at $19.87 on Tuesday. The firm has a market cap of $531.72 million, a P/E ratio of -3.27 and a beta of -0.30. The stock’s 50-day moving average is $23.25 and its 200-day moving average is $20.56. AnaptysBio has a one year low of $13.36 and a one year high of $27.50.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings results on Monday, March 11th. The biotechnology company reported ($1.59) EPS for the quarter, topping analysts’ consensus estimates of ($1.74) by $0.15. The company had revenue of $9.01 million for the quarter, compared to analyst estimates of $3.28 million. AnaptysBio had a negative return on equity of 119.42% and a negative net margin of 953.66%. Equities analysts anticipate that AnaptysBio will post -6.17 EPS for the current year.

Insider Transactions at AnaptysBio

In other news, CEO Daniel Faga sold 3,000 shares of the business’s stock in a transaction on Monday, March 25th. The stock was sold at an average price of $21.42, for a total transaction of $64,260.00. Following the completion of the transaction, the chief executive officer now owns 749,087 shares of the company’s stock, valued at approximately $16,045,443.54. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In related news, CEO Daniel Faga sold 3,000 shares of the business’s stock in a transaction on Monday, March 25th. The stock was sold at an average price of $21.42, for a total transaction of $64,260.00. Following the sale, the chief executive officer now owns 749,087 shares in the company, valued at approximately $16,045,443.54. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Eric J. Loumeau sold 5,000 shares of the business’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $25.00, for a total value of $125,000.00. Following the sale, the insider now owns 3,240 shares in the company, valued at approximately $81,000. The disclosure for this sale can be found here. In the last quarter, insiders sold 157,005 shares of company stock valued at $3,586,199. Corporate insiders own 35.50% of the company’s stock.

Institutional Investors Weigh In On AnaptysBio

Institutional investors have recently made changes to their positions in the stock. Allspring Global Investments Holdings LLC bought a new stake in shares of AnaptysBio in the 1st quarter valued at about $38,000. Quantbot Technologies LP purchased a new stake in shares of AnaptysBio in the second quarter worth approximately $34,000. China Universal Asset Management Co. Ltd. raised its stake in shares of AnaptysBio by 350.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 3,072 shares of the biotechnology company’s stock worth $66,000 after purchasing an additional 2,390 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of AnaptysBio by 248.8% in the third quarter. Tower Research Capital LLC TRC now owns 3,596 shares of the biotechnology company’s stock valued at $65,000 after acquiring an additional 2,565 shares in the last quarter. Finally, BNP Paribas Arbitrage SA grew its holdings in shares of AnaptysBio by 75.4% in the second quarter. BNP Paribas Arbitrage SA now owns 4,984 shares of the biotechnology company’s stock valued at $101,000 after acquiring an additional 2,142 shares in the last quarter.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.